Trials / Completed
CompletedNCT05130463
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,053 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin/Linagliptin | Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food. |
Timeline
- Start date
- 2022-03-22
- Primary completion
- 2024-04-08
- Completion
- 2024-07-08
- First posted
- 2021-11-23
- Last updated
- 2025-08-27
- Results posted
- 2025-08-27
Locations
30 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05130463. Inclusion in this directory is not an endorsement.